Interfering with the β-catenin-B9/B9L interactions with Bcl9/9L-ΔHD2 or β-catenin-D164A provoked a significant reduction in primary tumor growth, malignant tumor progression, and metastasis formation. The gene discussed is BCL9; the disease is cancer.